Antonio J Grillo-López

11.5k total citations · 4 hit papers
42 papers, 9.0k citations indexed

About

Antonio J Grillo-López is a scholar working on Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging and Genetics. According to data from OpenAlex, Antonio J Grillo-López has authored 42 papers receiving a total of 9.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pathology and Forensic Medicine, 21 papers in Radiology, Nuclear Medicine and Imaging and 14 papers in Genetics. Recurrent topics in Antonio J Grillo-López's work include Lymphoma Diagnosis and Treatment (31 papers), Monoclonal and Polyclonal Antibodies Research (20 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Antonio J Grillo-López is often cited by papers focused on Lymphoma Diagnosis and Treatment (31 papers), Monoclonal and Polyclonal Antibodies Research (20 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Antonio J Grillo-López collaborates with scholars based in United States, Switzerland and Puerto Rico. Antonio J Grillo-López's co-authors include Fernando Cabanillas, Christine A. White, Myron S. Czuczman, Ronald Levy, Thomas A. Davis, Russell J. Schilder, David G. Maloney, Ronald A. Castellino, Tim Lister and Sandra J. Horning and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Antonio J Grillo-López

42 papers receiving 8.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

1999 2.8k citations Bruce D. Cheson, Sandra J. Horning et al. Journal of Clinical Oncology profile →
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

1997 1.4k citations David G. Maloney, Antonio J Grillo-López et al. Blood profile →
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

2002 841 citations Thomas E. Witzig, Leo I. Gordon et al. Journal of Clinical Oncology profile →
Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

2000 523 citations Thomas A. Davis, Antonio J Grillo-López et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Antonio J Grillo-López United States	27	6.2k	3.6k	3.2k	2.7k	1.8k	42	9.0k
Christine A. White United States	22	4.6k 0.7×	2.8k 0.8×	2.9k 0.9×	2.5k 0.9×	1.7k 1.0×	34	7.1k
A.J. Grillo-López United States	24	4.3k 0.7×	2.9k 0.8×	2.5k 0.8×	2.7k 1.0×	1.9k 1.1×	42	7.0k
Myron S. Czuczman United States	50	6.5k 1.0×	4.6k 1.3×	2.5k 0.8×	3.5k 1.3×	1.9k 1.1×	241	10.4k
Félix Reyes France	25	5.5k 0.9×	3.7k 1.0×	891 0.3×	2.1k 0.8×	1.1k 0.6×	56	7.5k
Morton Coleman United States	47	4.8k 0.8×	3.0k 0.8×	1.5k 0.5×	3.3k 1.2×	1.2k 0.7×	306	8.2k
Tim Illidge United Kingdom	50	4.8k 0.8×	5.6k 1.5×	2.1k 0.7×	1.6k 0.6×	2.5k 1.4×	218	11.0k
Franck Morschhauser France	56	8.8k 1.4×	6.7k 1.8×	2.1k 0.6×	3.7k 1.4×	2.3k 1.3×	447	12.3k
Andrea Gallamini Italy	41	4.8k 0.8×	2.4k 0.7×	2.1k 0.6×	907 0.3×	911 0.5×	175	7.2k
Malik E. Juweid United States	31	4.7k 0.8×	2.7k 0.7×	3.5k 1.1×	984 0.4×	622 0.4×	126	8.1k
A. Z. S. Rohatiner United Kingdom	43	4.2k 0.7×	3.1k 0.9×	1.1k 0.3×	2.1k 0.8×	945 0.5×	117	6.8k

Countries citing papers authored by Antonio J Grillo-López

Since Specialization

Citations

This map shows the geographic impact of Antonio J Grillo-López's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio J Grillo-López with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio J Grillo-López more than expected).

Fields of papers citing papers by Antonio J Grillo-López

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio J Grillo-López. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio J Grillo-López. The network helps show where Antonio J Grillo-López may publish in the future.

Co-authorship network of co-authors of Antonio J Grillo-López

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio J Grillo-López. A scholar is included among the top collaborators of Antonio J Grillo-López based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio J Grillo-López. Antonio J Grillo-López is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grillo-López, Antonio J. (2013). The first antibody therapy for cancer: a personal experience. Expert Review of Anticancer Therapy. 13(4). 399–406. 3 indexed citations

Grillo-López, Antonio J. (2005). Is rituximab effective as a single agent in mantle-cell lymphoma?. Nature Clinical Practice Oncology. 2(10). 500–501. 4 indexed citations

Grillo-López, Antonio J. (2005). 90Y-ibritumomab tiuxetan: Rationale for patient selection in the treatment of indolent non-Hodgkin’s lymphoma. Seminars in Oncology. 32(1 Suppl 1). 44–49. 3 indexed citations

Czuczman, Myron S., et al.. (2004). Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up. Journal of Clinical Oncology. 22(23). 4711–4716. 265 indexed citations

Wiseman, Gregory A., Bryan R. Leigh, William D. Erwin, et al.. (2003). Radiation Dosimetry Results From a Phase II Trial of Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy for Patients With Non-Hodgkin's Lymphoma and Mild Thrombocytopenia. Cancer Biotherapy and Radiopharmaceuticals. 18(2). 165–178. 25 indexed citations

Grillo-López, Antonio J, Eric Hedrick, Michelle Rashford, & Mark Benyunes. (2002). Rituximab: Ongoing and future clinical development. Seminars in Oncology. 29(1). 105–112. 140 indexed citations

Grillo-López, Antonio J. (2002). Monoclonal Antibody Therapy for B-Cell Lymphoma. International Journal of Hematology. 76(5). 385–393. 31 indexed citations

Czuczman, Myron S., Alice Mohr, Carleton C. Stewart, et al.. (2002). Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Seminars in Oncology. 29(1). 36–40. 79 indexed citations

Wiseman, Gregory A., Leo I. Gordon, Pratik S. Multani, et al.. (2002). Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 99(12). 4336–4342. 212 indexed citations

10.

Grillo-López, Antonio J. (2002). AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients. Expert Review of Anticancer Therapy. 2(3). 323–329. 23 indexed citations

11.

Gordon, Leo I., Thomas E. Witzig, Ian W. Flinn, et al.. (2002). Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Seminars in Oncology. 29(1). 87–92. 55 indexed citations

12.

Byrd, John C., Timothy J. Murphy, Robin Howard, et al.. (2001). Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity. Journal of Clinical Oncology. 19(8). 2153–2164. 411 indexed citations

13.

White, Christine A., et al.. (2000). Antibody-Targeted Immunotherapy for Treatment of Non-Hodgkins Lymphoma. Current Pharmaceutical Biotechnology. 1(4). 303–312. 12 indexed citations

14.

Wiseman, Gregory A., Christine A. White, Michael Stabin, et al.. (2000). Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging. 27(7). 766–777. 189 indexed citations

15.

Cheson, Bruce D., Sandra J. Horning, B Coiffier, et al.. (1999). Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. Journal of Clinical Oncology. 17(4). 1244–1244. 2816 indexed citations breakdown →

16.

Pride, Michael W., Steve Shuey, Antonio J Grillo-López, et al.. (1998). Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen.. PubMed. 4(10). 2363–70. 22 indexed citations

17.

Maloney, David G., Antonio J Grillo-López, David Bodkin, et al.. (1997). IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma. Blood. 90(6). 2188–2195. 116 indexed citations

18.

Knox, Susan J., Michael L. Goris, Kirk Trisler, et al.. (1995). 148 90Y-anti-CD20 monoclonal antibody therapy for recurrent B cell lymphoma. International Journal of Radiation Oncology*Biology*Physics. 32. 215–215. 6 indexed citations

19.

Urba, Susan G., J. H. Doroshow, C. Cripps, et al.. (1992). Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck. Cancer Chemotherapy and Pharmacology. 31(2). 167–169. 34 indexed citations

20.

Gams, Richard A., et al.. (1985). A phase I trial of ametantrone acetate (NSC-287513). Investigational New Drugs. 3(4). 383–388. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact